ArticleInternational urology and nephrology2025
Early post-treatment remission of proteinuria is associated with long-term prognosis in patients with immunoglobulin A nephropathy.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of SGLT2 inhibitors on microscopic hematuria in IgA nephropathy: a review from the perspective of disease activity biomarkers.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo investigate the relationship between remission status and the optimal thresholds of proteinuria and hematuria after 6 months of treatment in patients with Immunoglobulin A Nephropathy (IgAN), and to assess their predictive value for long-term prognosis.
methodsA retrospective analysis was conducted on 440 IgAN patients. Receiver Operating Characteristic (ROC) curves were employed to determine the optimal thresholds for proteinuria and hematuria remission at 6 months post-treatment initiation. Patients were stratified into four groups based on these thresholds and their remission status. Comparative analysis of baseline clinical characteristics was performed across groups. Kaplan-Meier survival analysis was utilized to assess differences in composite kidney outcomes, and multivariate Cox regression analyses were conducted to evaluate the relationship between remission patterns and these outcomes.
resultsThe optimal thresholds for remission were identified as 0.80g/g for urinary protein and 13 RBC/μl for hematuria. Significant disparities in systolic blood pressure, diastolic blood pressure, body mass index, hemoglobin, serum creatinine, and estimated Glomerular Filtration Rate (eGFR) were observed among the four groups. During a median follow-up period of 33 months, 67 composite kidney events were recorded. Kaplan-Meier analysis revealed that patients achieving remission in both proteinuria and hematuria exhibited the highest survival rates, contrasting with the lowest rates in those with persistent proteinuria and hematuria (P < 0.001). Log-rank test analysis revealed no statistically significant differences in survival rates between the complete remission and proteinuria remission with persistent hematuria groups (P = 0.099), nor between the proteinuria persistence with hematuria remission and complete persistence groups (P = 0.513). Multivariate Cox analysis revealed that arteriolar hyalinosis is an independent risk factor for composite renal endpoint events in IgAN patients (HR, 2.687; 95%CI, 1.158-6.235; P = 0.021). Compared to the complete remission group, both the proteinuria persistence with hematuria remission group (HR, 8.649; 95%CI, 2.353-31.792; P = 0.001) and the complete persistence group (HR, 6.580; 95%CI, 1.936-22.360; P = 0.003) exhibited significantly higher risks of reaching endpoint events. Elevated baseline hemoglobin levels can reduce the risk of disease progression in IgAN patients (HR, 0.982; 95%CI, 0.967-0.996; P = 0.013).
conclusionProteinuria remission is significantly associated with long-term prognosis in IgAN patients. Achieving proteinuria levels below 0.80 g/g after 6 months of initial treatment may indicate favorable control targets in IgAN management.
Indexed as
Identifiers
40317431What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.